NL9102071A - Geneesmiddelen. - Google Patents

Geneesmiddelen. Download PDF

Info

Publication number
NL9102071A
NL9102071A NL9102071A NL9102071A NL9102071A NL 9102071 A NL9102071 A NL 9102071A NL 9102071 A NL9102071 A NL 9102071A NL 9102071 A NL9102071 A NL 9102071A NL 9102071 A NL9102071 A NL 9102071A
Authority
NL
Netherlands
Prior art keywords
indole
ethyl
methyl
dimethylamino
methanesulfonamide
Prior art date
Application number
NL9102071A
Other languages
English (en)
Dutch (nl)
Inventor
Derek Leslie Crookes
Joanne Craig
Stephen John Skittrall
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NL9102071A publication Critical patent/NL9102071A/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
NL9102071A 1990-12-12 1991-12-11 Geneesmiddelen. NL9102071A (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments
GB9026998 1990-12-12

Publications (1)

Publication Number Publication Date
NL9102071A true NL9102071A (nl) 1992-07-01

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
NL9102071A NL9102071A (nl) 1990-12-12 1991-12-11 Geneesmiddelen.

Country Status (36)

Country Link
US (2) US5554639A (de)
EP (1) EP0490689B1 (de)
JP (1) JP2994037B2 (de)
KR (1) KR100211479B1 (de)
CN (2) CN1030890C (de)
AP (1) AP230A (de)
AT (1) ATE119881T1 (de)
AU (1) AU650706B2 (de)
BE (1) BE1005085A3 (de)
CA (1) CA2098302C (de)
CH (1) CH684192A5 (de)
CY (1) CY2005A (de)
CZ (1) CZ281931B6 (de)
DE (1) DE69108200T2 (de)
DK (1) DK0490689T3 (de)
EG (1) EG20219A (de)
ES (1) ES2069836T3 (de)
FR (1) FR2670487B1 (de)
GB (2) GB9026998D0 (de)
GR (1) GR3015430T3 (de)
HK (1) HK82697A (de)
HU (1) HU211937A9 (de)
IE (1) IE62894B1 (de)
IL (1) IL100330A (de)
IS (1) IS1706B (de)
IT (1) IT1252868B (de)
MX (1) MX9102501A (de)
MY (1) MY109265A (de)
NL (1) NL9102071A (de)
NZ (1) NZ240942A (de)
PT (1) PT99757B (de)
RU (1) RU2108328C1 (de)
TW (2) TW205035B (de)
WO (1) WO1992010477A1 (de)
YU (1) YU48926B (de)
ZA (1) ZA919750B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK279211B6 (sk) * 1992-06-05 1998-08-05 Merck Sharp & Dohme Limited Sulfátová soľ substituovaného triazolu, spôsob jej
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6132757A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6562838B2 (en) 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6458804B1 (en) * 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
WO2003032983A1 (en) * 2001-06-05 2003-04-24 Ronald Aung-Din Transdermal migraine therapy
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
WO2005119607A2 (en) * 2004-06-03 2005-12-15 Tyfone, Inc. System and method for securing financial transactions
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
EP2026790A2 (de) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Kombinationstherapie zur behandlung von epilepsie und assoziierten erkrankungen
EP2813144A1 (de) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgetische Zusammensetzungen enthaltend ein Antihistamin
DE602007013440D1 (de) * 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
ES2620672T3 (es) 2008-01-09 2017-06-29 Charleston Laboratories, Inc. Comprimidos de doble capa que comprenden oxicodona y prometazina
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
WO2009143571A1 (en) 2008-05-27 2009-12-03 Biota Scientific Management Pty Ltd Antiviral salts
WO2009152551A1 (en) * 2008-06-20 2009-12-23 Alphapharm Pty Ltd Pharmaceutical formulation
AU2009271362B2 (en) 2008-06-23 2014-03-13 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8592424B2 (en) * 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
WO2011036521A2 (en) 2009-09-25 2011-03-31 Dr. Reddy's Laboratories Limited Formulations comprising triptan compounds
US10716766B2 (en) 2015-03-02 2020-07-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
ES2842523T3 (es) 2015-05-15 2021-07-14 Univ Michigan Regents Métodos y composiciones para el tratamiento de la artritis
EP3423041A4 (de) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
EP3706744B1 (de) 2017-11-07 2022-08-17 The Regents of The University of Michigan Kleinmolekülige inhibitoren von geteilten epitop-calreticulin-wechselwirkungen und verwendungsverfahren
WO2020049523A1 (en) 2018-09-07 2020-03-12 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
EP4110337A4 (de) * 2020-02-27 2024-03-20 Pfizer Ireland Pharmaceuticals Orale schnelldispergierende darreichungsform von rimegepant

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
IE62894B1 (en) 1995-03-08
PT99757A (pt) 1992-12-31
NZ240942A (en) 1994-03-25
IE914317A1 (en) 1992-06-17
TW205035B (de) 1993-05-01
MX9102501A (es) 1992-09-01
IS1706B (is) 1998-12-10
AP230A (en) 1993-01-27
CY2005A (en) 1997-12-05
HU211937A9 (en) 1996-01-29
RU2108328C1 (ru) 1998-04-10
IL100330A (en) 1996-06-18
TW300886B (de) 1997-03-21
YU191491A (sh) 1994-04-05
JP2994037B2 (ja) 1999-12-27
CZ281931B6 (cs) 1997-04-16
DE69108200T2 (de) 1995-07-20
AU650706B2 (en) 1994-06-30
CA2098302C (en) 2001-10-16
CA2098302A1 (en) 1992-06-13
BE1005085A3 (fr) 1993-04-13
HK82697A (en) 1997-06-27
ES2069836T3 (es) 1995-05-16
GB9126297D0 (en) 1992-02-12
EP0490689A1 (de) 1992-06-17
GB2251614B (en) 1994-12-14
ZA919750B (en) 1992-10-28
ITRM910922A0 (it) 1991-12-11
DK0490689T3 (da) 1995-05-22
KR100211479B1 (ko) 1999-08-02
CN1063099A (zh) 1992-07-29
MY109265A (en) 1996-12-31
CH684192A5 (fr) 1994-07-29
FR2670487A1 (fr) 1992-06-19
DE69108200D1 (de) 1995-04-20
PT99757B (pt) 1999-05-31
JPH06503560A (ja) 1994-04-21
US5554639A (en) 1996-09-10
ATE119881T1 (de) 1995-04-15
IS3790A7 (is) 1992-06-13
AP9100339A0 (en) 1992-01-31
EP0490689B1 (de) 1995-03-15
WO1992010477A1 (en) 1992-06-25
CN1030890C (zh) 1996-02-07
GR3015430T3 (en) 1995-06-30
EG20219A (en) 1997-11-30
CN1128259A (zh) 1996-08-07
CN1050831C (zh) 2000-03-29
IL100330A0 (en) 1992-09-06
CZ114093A3 (en) 1994-02-16
GB2251614A (en) 1992-07-15
US5705520A (en) 1998-01-06
GB9026998D0 (en) 1991-01-30
AU9072091A (en) 1992-07-08
YU48926B (sh) 2002-12-10
ITRM910922A1 (it) 1993-06-11
FR2670487B1 (fr) 1993-08-20
IT1252868B (it) 1995-06-28

Similar Documents

Publication Publication Date Title
NL9102071A (nl) Geneesmiddelen.
RU2762725C2 (ru) Композиции, содержащие триптановые соединения
US5393773A (en) Method for the intranasal administration of 3-[2-(dimethylamino)-ethyl]-H-methyl-1H-indole-5-methanesulphonamide
JPH01153639A (ja) 鼻又は目に使用する薬剤及びその製造法
CA2392050C (en) Pharmaceutical formulations containing zolmitriptan
RU2130022C1 (ru) N,n-диметил-2-[5-(1,2,4-триазол-1-илметил)-1н-индол-3-ил] этиламина сульфатная соль (2:1) и ее фармацевтически приемлемые гидраты, способы ее получения, фармацевтическая композиция на ее основе, способ ее получения и лекарственное средство
RU2242231C2 (ru) Парентеральная композиция для лечения эпилепсии
JP2021514393A (ja) 複数回使用のトラセミド組成物
RU2710372C2 (ru) Композиции, содержащие триптановые соединения
KR100384346B1 (ko) 엘레트립탄 헤미술페이트 및 카페인을 포함하는 약제학적조성물
NO179102B (no) 3-[2-(dimetylamino)etylÅ-N-metyl-1H-indol-5-metansulfonamid
JPS6133127A (ja) 医薬活性化合物の包接化方法
JPH11508916A (ja) トリアゾリルメチル−インドールエチルアミン重硫酸塩
JP2011173801A (ja) ケトチフェン配合水性組成物

Legal Events

Date Code Title Description
BV The patent application has lapsed